Publication date: Sep 04, 2019
Gut microbiota have been studied in relation to the pathophysiology of Parkinson’s disease (PD) due to the early gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies, various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset to atypical parkinsonism cohorts, prodromal and treatment-nacEFve de novo PD subjects, measurements of fecal microbial concentrations and a multi-omics assessment are required to provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.
Boertien, J.M., Pereira, P.A.B., Aho, V.T.E., and Scheperjans, F. Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson’s Disease: A Systematic Review. 22234. 2019 J Parkinsons Dis.
- Gut Microbiota Differs Between Parkinson’s Disease Patients and Healthy Controls in Northeast China.
- Altered Gut Microbiome in Parkinson’s Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model.
- High-throughput 16S rRNA gene sequencing reveals that 6-hydroxydopamine affects gut microbial environment.
- Probiotics for Parkinson’s Disease.
- Potential of Prebiotic Butyrogenic Fibers in Parkinson’s Disease.
- Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain.
- Enterin’s RASMET Study Published